相关实验视频
Updated: Jul 16, 2025

10:37
Development of Recombinant Proteins to Treat Chronic Pain
Published on: April 11, 2018
9.6K
德克萨米他通过糖解和线粒体相关途径抑制IL-8,以调节炎症性疼痛
Ren He1, Xiaohan Li1, Silun Zhang1
1Department of Anesthesiology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University, Health Science Center, No. 3002, Futian District, Shenzhen, Guangdong Province, 518035, China.
BMC anesthesiology
|September 18, 2023
概括
德克萨米他通过糖解和线粒体路径减少IL-8来缓解炎症性疼痛. 这项研究阐明了德克萨米他背后的机制.
科学领域:
- 生物医学科学 生物医学科学
- 疼痛研究 疼痛研究
- 分子生物学分子生物学
背景情况:
- 德克萨米他 (Dexa) 显示了与INTERLEUKIN-8 (IL-8) 相关的止痛作用.
- 德克萨米他通过糖解和线粒体相关途径诱导反受体的精确机制在很大程度上仍未被阐明.
研究的目的:
- 调查糖解和线粒体通路在德克萨米他镇痛作用中的作用.
- 探索德克萨米他与这些代谢途径中的关键蛋白质之间的相互作用.
主要方法:
- 在小鼠中使用完整的弗洛恩德辅助剂 (FCA) 诱导炎症性疼痛.
- 用弗雷测试测量了的戒断值.
- 通过Western blot和ELISA分析了糖解和线粒体通路蛋白以及IL-8水平;分子对接评估了Dexa-PKM2相互作用.
主要成果:
- 德克萨 (Dexa) 在接受FCA治疗的小鼠中表现出显著的止痛作用,这种作用通过糖解 (2-脱氧葡萄糖) 和线粒体 (奥利戈美) 抑制剂被逆转.
- 德克萨通过降低GLUT3和增加PKM2来调节糖解,显示与果糖-1,6-双酸盐 (FBP) 的潜在相互作用.
- 德克萨降低了线粒体通路中的Mfn2,而德克萨,2-脱氧葡萄糖和寡糖素降低了IL-8水平.
结论:
- 德甲通过调节糖解和线粒体通路蛋白来减弱IL-8的表达.
- 这些分子机制在炎症性疼痛模型中支了德克萨米他的止痛作用.
相关概念视频
T Cell Types and Functions
1.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.1K
Inflammatory Response
2.1K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
2.1K
Analgesia and Pain Management
652
Pain is critical to various clinical pathologies, provoking an urgent need for effective management. Pain, whether acute or chronic, is a complex neurochemical process. Its alleviation depends on the type, with nonopioid analgesics effective for mild to moderate pain, such as musculoskeletal or inflammatory pain, while neuropathic pain responds best to anticonvulsants, tricyclic antidepressants, or serotonin/norepinephrine reuptake inhibitors. For severe acute or chronic pain, opioids may be...
652
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
190
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
190
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
144
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
144
NF-κB-dependent Signaling Pathway
7.5K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
7.5K

